Emmaus Life Sciences, Inc. today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.
Read More
Emmaus Life Sciences, Inc. today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari.
Read More
Emmaus Life Sciences today announced the submission of its application for marketing authorization of Endari® to the United Arab Emirates (U.A.E.) Ministry of Health.
Read More
Agreement Expands on the Companies’ Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies
Read More
OTC Markets Group Inc. (OTCQX: OTCM) today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA) has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.
Read More